source
- Researchers suspect Exelixis used a minor tweak to cabozantinib to sidestep patent cliffExelixis' 2025 financial results highlighted the importance of its drug cabozantinib, which has been a major revenue source for the company. A group of analysts argue that the company introduced a…
- Hims & Hers says it can quickly launch six wellness peptides if FDA lifts banHims & Hers used its second‑quarter earnings call to explain that it is preparing to offer six consumer wellness peptides that are currently prohibited for compounding pharmacies. The company says…